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Summary
Introduction: Several calculation tools or scales have been developed in recent years to assess the risk
of fracture due to long-term fragility. The Garvan  calculator has not been validated in the Spanish popu-
lation. This study aims to observe their predictive capacity in a population sample of the Canary Islands
and, therefore, of the Spanish population.
Material and Methods: We included 121 patients who were followed up for 10 years in our consultations. All
were assessed the risk of fracture using the Garvan calculator and based on the data obtained in the first visit.
Results: Of the 121 patients, 30 suffered at least one osteoporotic fracture over the 10-year follow-up
period. The group of patients with fractures had on the Garvan scale an average risk value to suffer any
fracturing fracture of 27%, compared to 13% of those who did not suffer fracture (p<0.001). The area
under the corresponding ROC curve was 0.718 (CI-95% = 0.613 ; 0.824). Based on this, the estimated opti-
mal cut-off point to consider a high risk fracture was 18.5%. This value corresponded to a sensitivity of
0.67 (CI-95% = 0.47 ; 0.83) and a specificity of 0.67 (CI-95% = 0.56 ; 0.77).
Conclusions: Our results show that the Garvan scale adequately predicts the risk of 10-year osteoporotic
fracture in our population. A value lower than 18.5% would allow us to establish a low fracture risk and
could be used as a screening tool.
Key words: osteoporosis, risk, fracture, scale, Garvan calculator, Spanish population.
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Introduction
Osteoporosis is a very prevalent disease, which
produces the so-called "fragility fractures" as the
only clinical complication1. In recent years, several
calculation tools or scales have been published
which, based on clinical data and with or without
the aid of bone densitometry, estimate the risk of
a fracture in the long term, up to 10 years2-6.
Although these scales share many clinical data
such as age or history of previous fractures, they
also differ in the methodology and population in
which they have been developed, as well as whe-
ther or not they include bone densitometry or
other risk factors. For example, the more widely
used FRAX® scale, published in more studies and
sponsored by the World Health Organization
(WHO)3, apparently underestimates the risk of
fracture in both patients with certain diseases7-12 as
well as globally in some countries, such as Spain13,
Argentina14 or Canada15.
The Garvan fracture risk calculator or Garvan
scale was devised by Australian researchers at the
Garvan Institute of Medical Research. It has been
less widely used than the FRAX®, showing often
divergent results in some studies which compared
both scales16-18. It has not been validated in Spain,
which led us to carry out this study, with the aim
of observing its validity in a Canary Island popu-
lation of both sexes. We have considered exten-
ding it to the Spanish population.
Material and methods 
Design: This prospective study initially included
400 people of both sexes whose densitometries at
the time of the first visit showed no osteoporotic
values. The subjects had attended at least a second
follow-up visit. Subsequently, those patients who
were monitored over 10 years and who had not
undergone pharmacological treatment for osteo-
porosis in those years were selected. The 121 who
met this criterion were included in the follow-up
study.
Fractures in the first 10 years of follow-up:
All 121 individuals included in the study presented
fragility fractures that occurred during the 10-year
follow-up period.
Application of the Garvan calculator: All the
patients included in our study were assessed for
fracture risk due to long-term fragility using the
Garvan calculator based on the data obtained
during the first consultation. The tool considers a
total of 5 calculation variables: sex, age, presence of
fragility fractures beyond 50 years of age and falls
in the last 12 months. The determination of bone
mineral density by densitometry may be added if
we have it. Otherwise, the calculation is also carried
out, but the program requires including weight. In
our study, all patients underwent bone densito-
metry screening at the first visit. This scale is freely
available, without registration, on-line at:
https://www.garvan.org.au/promotions/bone-
fracture-risk/calculator/
Once the data has been entered, the calculator
shows the risk of frailty fracture for: a) any fragi-
lity fracture, and b) specifically hip fracture, and
both at 5 and 10 years.
Statistical Study
Univariate analysis: Categorical variables were
expressed as frequencies and percentages, and the
continuous variables as means and standard
deviations when the data followed a normal distri-
bution, and as medians and interquartile ranges
(percentiles 25-75) when the distribution followed
was not normal. The percentages were compared
using the chi-square test, the means with Student’s
t test, and the medians with the Wilcoxon test for
independent data.
Survival analysis: To explore the predictive
ability of the fracture risk of the Garvan calculator,
patients were classified according to the tertiles
corresponding to this predictor. In each of these
groups the survival curves were estimated up to
the appearance of the first fracture using the
Kaplan-Meier method. The difference between
them was contrasted using the log-rank test.
Receiver Operating Characteristics (ROC)
Curves: In order to evaluate the discriminatory
capacity of any frailty fracture risk, the 121
patients who were monitored over 10 years were
classified according to whether or not they suffe-
red at least one fracture during this time period.
For this classification, a ROC analysis was carried
out, estimating the area under the corresponding
ROC curve with a 95% confidence interval. The
Garvan scale’s discriminatory optimal threshold
was selected as the value associated with the point
of the ROC curve that minimized the quantity:
(1 - sensitivity)2 + (1 - specificity)2
Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were
estimated for this threshold with 95% confidence
intervals. 
A hypothesis test was considered statistically
significant when the corresponding p value was
less than 5%. Data were analyzed using the R pro-
gram (version 3.1.0.).
Results
Table 1 shows the baseline characteristics of the
400 patients initially recruited for this study. It is
observed that there is a greater proportion of
women than men and that the mean age was 63
years, without obtaining statistically significant dif-
ferences between both sexes. As expected, males
were larger in size and weight than females, but
body mass index (BMI) was similar in both
groups, with an overweight average. The overall
median risk of fracture fractures at 10 years when
Garvan was applied was 15%, significantly higher
in females than in males (p<0.001).
Table 2 shows the characteristics of the studied
population over 10 years from the time of the
Garvan estimation. The total number of patients
was 121, of which 30 had at least one fracture due
to fragility in this time frame. None of the patients
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received anti-osteoporotic treatment, although the
patients with fractures were indicated after the
fracture occurrence was reported. Of all the oste-
oporotic fractures (vertebral, hip, Colles, humerus,
tibia, and ribs) only two were of the hip. At the
outset of the study, the fractured patients had a
mean risk of suffering any fragility fracture of 27%,
compared to 13% of those who did not suffer a
fracture (p <0.001). The same significant result
was observed with the risk of hip fracture, since
patients who suffered a new osteoporotic fracture
(of any type) during follow-up showed an avera-
ge value of 8% versus 3% of non-fractured ones.
Table 3 shows the statistical parameters used to
assess the ability of the Garvan scale to predict
any fracturing fracture within 10 years after its
determination in the study population. The area
under the corresponding ROC curve was 0.718
(CI-95% = 0.613 ; 0.824) (Figure 1). Considering
this ROC curve, and looking for the value that
offered the best statistical conditions to predict the
risk of fracture, we set the optimum cutoff point at
18.5%. This value corresponds to a sensitivity of
0.67 (IC-95% = 0.47 ; 0.83), a specificity of 0.67 (CI
-95% = 0.56, 0.77), a predictive value of 0.86 (CI-
95% = 0.76 ;  0.93) and a positive predictive value
of 0.40 (CI-95% = 0.26 ; 0.55).
Figure 2 shows the survival curves for the
period between the estimation of the risk of frailty
fracture and the first fragility fracture in each of
the cohorts determined by the tertiles of the
Garvan scale. According to these tertiles, the
groups were divided according to whether the
value obtained was less than 11% between 11 and
22%, and higher than 22%. The log-rank test sho-
wed statistically significant differences at 5 years
(p<0.001).
The limited number of hip fractures (only 2)
prevented an ROC analysis and one of survival for
this type of fracture.
Discussion
In recent years, the diagnosis and treatment of
patients with osteoporosis have changed, as a
series of calculation tools or risk scales have been
developed that allow us to estimate the probabi-
lity of suffering a fracture due to fragility in the
future, usually 10 years. This differs from the risk
estimation offered by bone densitometry, which,
in isolation, reports only a part of the fracture risk,
which is clearly multifactorial19,20. Therefore, the
combination of fracture risk factors and the results
of densitometry have a greater specificity and sen-
sitivity than each of them separately21. The FRAX®
and Garvan scales, in contrast to QFracture®,
include the value of bone mineral density per
DXA in calculations for the likelihood of fracture
risk.
The definitive role of these scales has not been
established, although their presence is increasing
in position papers and clinical guidelines.
Currently, FRAX® is the most accepted scale. It
was the first to be published and is sponsored by
the WHO22. It allows researchers to calculate frac-
ture risk in a large number of countries. It is the
tool with the greatest amount of literature publis-
hed, with a treatment threshold of more than 20%
for any fragility fracture and 3% for a hip fracture23.
However, the FRAX® scale also has its limitations.
On the one hand, it does not include falls, a very
important risk factor in the production of most fra-
gility fractures24,25. On the other hand, several
authors have expressed their concern as it unde-
restimates the risk of fracture in diabetic patients
and in the Spanish population12,13, because this
scale has not yet been corrected for Spain. Finally,
the formula with which the FRAX® calculator has
been developed has not been published, a fact
that has generated great controversy and suspicion
in the scientific community.
Another fracture risk calculator is the
QFracture®5,26, developed by English authors, who
added additional risk factors such as falls, diabetes
mellitus and other diseases to variables already
included in the FRAX® scale (http: //www.qfractu-
re.org). In addition, the degree of alcohol and
tobacco consumption was incorporated in more
detail, and it has the novelty of making it possible
to estimate fracture risk from 1 to 10 years, very
useful for those individuals whose life expectancy
is lower.
As for the limitations of QFracture® tool, it does
not include calculations of bone densitometry and
contains many variables5,26, so the time required to
complete the questionnaire is significantly longer.
In addition, the QFracture® scale is not as widely
used as FRAX®, which may be because it has not
been validated outside the UK, and therefore there
is less published material about this tool. On the
other hand, the optimal cutoff points for the clini-
cal management of patients with osteoporosis
have not been established. Its website suggests a
risk estimate for women of 11.1% in 10 years and
for men, 2.6% over the same period of time.
Finally, there are few comparative studies bet-
ween the QFracture® and FRAX® scales. We have
been able to find only the work of Johansen et al.
Who considered QFracture® better as a tool for
estimating hip fracture risk, since it includes the
history of falls27. On the other hand, Kanis et al
published a review of the Scottish Intercollegiate
Guidelines Network (SIGN), which concluded that
the use of QFracture® should be used for estima-
ting hip fracture risk and not for the risk of fragi-
lity fractures19.
The Garvan fracture risk calculator was publis-
hed by a group of Australian researchers from the
Garvan Institute of Medical Research to predict in
a given patient the absolute risk of having any
osteoporotic fracture within 5 and 10 years. The
study included a sample of more than 2,500 indi-
viduals, men and women, over 60 years of age
from data collected by the Dubbo study28. They
included the following four risk factors: age, num-
ber of previous fractures after 50 years of age,
number of falls in the last year and the value of
bone mineral density or weight (if bone densito-
metry is not available).
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Table 1. General characteristics of the population recruited at the beginning of the study
Table 2. Characteristics of the studied population for 10 years from the time of the estimation of the Garvan
value
Table 3. Capacity of the Garvan scale to predict an osteoporotic fracture within 10 years of being calculated
Total
N = 400
Men
N = 38
Women
N = 362 Value p 
Age, years (#) 63.3 ± 8.9 63.8 ± 9.1 63.3 ± 8.9 0.736
Weight, kg (#) 67.9 ± 13.2 78.7 ± 13.7 66.8 ± 12.6 <0.001
Size, cm (#) 157.1 ± 7.3 169.7 ± 6.1 155.7 ± 6.0 <0.001
BMI*, kg/m2 (#) 27.5 ± 4.9 27.3 ± 4.2 27.6 ± 5.0 0.741
Garvan value for any 10 year frailty
fracture, % (&) 15 (10 ; 29) 8 (4 ; 14.7) 15 (10 ; 29) <0.001
Garvan value for 10 year hip fracture,
% (&) 3 (1 ; 8.25) 0.95 (0.42 ; 3) 3 (1 ; 9) <0.001
Data expressed as #: means ± standard deviations; &: medians (interquartile ranges). 
*BMI: body mass index.
*Fractures occurring within 10 years of follow-up.
Data expressed as #: means ± standard deviations; &: medians (interquartile ranges).
Fractures*
Total
N = 121
No
N = 91
Yes
N = 30 P
Age, years (#) 59.3 ± 6.8 58.2 ± 6.4 62.8 ± 6.7 0.001
Weight, kg (#) 66.8 ± 11.7 67.4 ± 12.5 64.9 ± 8.8 0.309
Size, cm (#) 156.4 ± 6.0 156.6 ± 5.9 155.7 ± 6.3 0.439
BMI, kg/m2 (#) 27.3 ± 4.7 27.5 ± 5.0 26.8 ± 3.6 0.503
Garvan value for any 10 year frailty
fracture, % (&) 15 (10 ; 28) 13 (9.5 ; 23) 27 (14.2 ; 43.2) <0.001
Garvan value for 10 year hip fracture,
% (&) 3 (1 ; 8) 2 (1 ; 6.5) 8 (3 ; 17) <0.001
Parameter Estimate (IC-95%)
Area under the ROC curve 0.718 (0.613 ; 0.824)
Cut off point 18.5
Sensitivity 0.67 (0.47 ; 0.83)
Specificity 0.67 (0.56 ; 0.77)
Positive predictive value 0.40 (0.26 ; 0.55)
Negative predictive value 0.86 (0.76 ; 0.93)
Positive likelihood ratio 2.02 (1.37 ; 2.98)
Reason for negative likelihood 0.50 (0.29 ; 0.84)
ORIGINALS / Rev Osteoporos Metab Miner. 2017;9(2):55-61
59
The Garvan scale, although
apparently very practical and
easy to use, is hampered by the
limited relevant bibliography
and that it has not been valida-
ted outside Australia.
In the main, existing publi-
cations compare the FRAX®
scale with QFracture®, and
FRAX® with the Garvan calcula-
tor29. Several studies have con-
cluded that the FRAX® tool with
bone mineral density (BMD)
measurement underestimates
the incidence of osteoporotic
fractures, while both FRAX®
without BMD and the Garvan
scale overestimate the incidence
of these fractures6,30. However,
although the FRAX® and Garvan
calculators include different risk
factors, the therapeutic recom-
mendation is the same18.
As the Garvan scale has
not yet been validated in
Spain, the main contribution
of our study is to give reliabi-
lity to its predictive capacity in
our population, which would
allow its use in our patients,
and with this the estimation of
the risk of fracture due to fra-
gility of A faster way than with
the QFracture® scale, and a
transparent methodology in its
elaboration and with the inclu-
sion of the falls, facts that the
FRAX® does not offer.
With the FRAX® and
QFracture® scales, an attempt
has been made to identify a
cutoff point from which we
would consider the patient to
be at high risk of fracture due
to fragility and, therefore, it
would be advisable to initiate
some treatment. As we mentio-
ned earlier, in the FRAX® scale,
this value has been set at 20%
for any fragility fracture and 3%
for the hip, whereas in
QFracture®, the authors recom-
mend considering cut-off
points for women and Men at
11.1% and 2.6%, respectively.
In the Garvan calculation
tool this cut-off point has not
yet been clearly established.
According to our study results,
an estimate of the risk of suffe-
ring any frailty fracture below
18.5% would be indicative of a
very low risk, so starting treat-
ment would not be necessary.
Figure 1. ROC curve for the risk of suffering any fracturing fracture cal-
culated with the Garvan scale
Figure 2. Survival curves up to the first fracture according to the groups
defined by the tertiles of the Garvan value for risk of any fragility fracture
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The main weakness of our study is the small
sample size, due to the enormous difficulty found
in our consultations of patients without densito-
metric osteoporosis and with a follow-up over so
many years, besides not having received anti-oste-
oporotic treatment until the first fracture. The
same reason has prevented us from performing
the calculations for hip fracture risk, since the
number of fractures incident at this location was
insufficient to obtain a conclusive statistic. Despite
this, the statistical study performed had enough
robustness to be able to validate our findings.
In conclusion, according to the results of our
study, the Garvan calculator can be used to a
ccess osteoporotic fracture risk in our popula-
tion. Likewise, it could be used as a screening tool,
since, according to the statistical calculations obtai-
ned, a value lower than 18.5% would allow us to
establish in a given patient a very low risk of suffe-
ring any fragility fracture in the following 10 years.
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